UBS: China Life (02628.HK) reports better-than-expected interim results and reiterates "buy" rating.

According to the Wisdom Finance APP, UBS released a research report stating that it has raised its 2026 net profit forecast for China Life (02628.HK) by 37% to reflect the profit forecast for the first half of the year and the macroeconomic environment so far in the second half of the year. UBS reiterated its "buy" rating on China Life and maintained a target price of HK$40 for its H shares.